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Abstract  
Purpose: There is a rising interest in measuring the societal burden of malignancies including 
prostate cancer. However, population-based studies reporting incidence costs of prostate cancer 
in the long-term are lacking in Europe. The objectives of the study is to analyse the long-term 
costs and survival of prostate cancer patients treated by radical prostatectomy (RP) or 
conservative management (nRP).  
Methods: A retrospective claims data analysis of the National Health Insurance Found 
Administration of Hungary between 01.01.2002 and 31.10.2013 was carried out. Annual 
incidence costs related to prostate cancer and overall survival were calculated for a cohort of 
patients diagnosed between 2002 and 2005.  
Results: Altogether 17,642 patients were selected, 2,185 (12%) of them have undergone RP. 
The annual incidence rate ranged between 4,177-4,736 cases. Mean age of RP and nRP patients 
were 59.4 (SD 5.9) and 71.0 (8.4) years, respectively. The mean survival time of the RP patients 
was significantly longer compared to nRP patients both in the total sample (11.2 vs. 7.4 years; 
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p<0.001) and in the subgroup <70 years (11.3 vs 8.8 years; p<0.001). At the end of the 12-year 
follow-up, RP patients had a higher (0.83 vs 0.68), while nRP patients had a slightly lower (0.35 
vs. 38) probability of being alive compared with the age-matched general male population. The 
long-term cumulative costs of the RP and nRP patients amounted to €4,448 and €8,616. Main 
driver of the cost difference was high drug cost in the nRP group.  
Conclusions: To our knowledge, this study applied the longest time-window in reporting 
population-based incidence costs in Europe. We found that RP patients not only lived longer, 
but they had significantly lower total long-term costs than nRP patients. Therefore radical 
prostatectomy is a cost-effective strategy in prostate cancer. 
 
 
Key words: prostate cancer, cost-of-illness, administrative claims, survival, radical 
prostatectomy 
 
Introduction 
In Europe, prostate cancer is the most common malignancy among men (96.0 cases per 
100,000) followed by lung (68.3 cases per 100,000) and colorectal cancer (55.7 cases per 
100,000), and the third leading cause of cancer deaths (19.3 deaths per 100,000) [1,2]. The 
majority (55%) of incident cases of prostate cancer occur over the age of 70 years [3]. In 
Hungary, the number of incident cases for the year 2011 ranged between 3,419 and 4,117 based 
on the data of the National Health Insurance Fund Administration (NHIFA) and of the National 
Cancer Registry [4,5].  
There is a rising interest in measuring the societal burden of malignancies due to limited 
resources and cost escalation in the healthcare sector. Incidence costs of diseases are reported 
less frequently than prevalence-based average annual costs. Although prevalence-based cost 
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studies are helpful in estimating the costs of prostate cancer at a given time point, they provide 
little insight in the long-term costs associated with incident cases. In the US, one study using 
the SEER-Medicare database, reported the incidence and life-time costs of prostate cancer in 
the past 20 years [6]. No such study has been identified from Europe according to a systematic 
review on the costs of prostate cancer by Rencz et al. [7]. Their literature search, however, was 
closed in 2013. Since then, only one population-based cost study by Laudicella et al. has 
reported incidence costs of prostate cancer over a 9-year period (3 years observation and 6 years 
projections) for England [8]. Incidence costs in prostate cancer have not been investigated in 
Hungary, so far only data on average annual costs were reported [9,4].  
 
Newly diagnosed patients aged over 70 years are more likely to receive conservative, non-
radical prostatectomy (nRP) treatment due to various reasons including the increased risk of 
complications [10]. The majority of the patients undergoing radical prostatectomy (RP) are 
under the age of 70 years [11,12]. Nevertheless, there is a shortage of data on the cost 
consequences of RP in the long-term. Therefore, our study aims to analyse and compare the 
long-term costs and survival of the RP and nRP patients from a payer perspective. 
 
 
Methods 
We analysed the claims data of the NHIFA between January 1st, 2001 and December 31st, 2013. 
NHIFA is a single health insurer in Hungary covering the whole population of the country 
(approximately 10 million people) across all types of care (primary, secondary care, 
pharmaceutical claims, etc.). Male patients over the age of 30 years were selected in multiple 
steps based on international classification codes (ICD-10) for prostate cancer (C61 - Malignant 
neoplasm of prostate or D07.5 - Carcinoma in situ of other and unspecified genital organs, 
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prostate or D40.0 - Neoplasm of uncertain or unknown behaviour of male genital organs, 
prostate) and having prostate biopsy and androgen-deprivation therapy, or radical 
prostatectomy, or radiotherapy [13]. 
Disease duration was calculated as the time between the date of the first occurrence of the ICD 
code of prostate cancer in a patient’s claim records and the date of death or the study endpoint. 
The following data were collected: date of birth and death, date of first occurrence of ICD code 
for prostate cancer, date of diagnosis of bone metastases and the date of radical prostatectomy. 
Moreover, prostate cancer-related healthcare utilisation and expenses were collected including 
outpatient visits, hospital admissions and the use of the following prescription drugs: buserelin, 
leuprorelin, goserelin, triptorelin, flutamid, nilutamid, bicalutamid, abiraterone, degarelix and 
cabazitaxel. 
A cohort of patients diagnosed with prostate cancer between 2002 and 2005 was selected from 
the NHIFA database. Patients diagnosed with prostate cancer in 2001 were excluded in order 
to guarantee that only new cases without medical history of prostate cancer are involved. In 
order to have the longest possible period without the need for censoring, patients diagnosed 
after 2005 were also excluded. Observational period varied between 8-11 years. 
 
Cost calculation 
Reimbursement data from the NHIFA were used to estimate the cost associated with prostate 
cancer. In Hungary, active inpatient care is reimbursed through the diagnosis-related groups 
(DRG) system, while outpatient services are funded on an activity basis. Data about direct 
medical costs were obtained directly from the administrative claims database. All prostate 
cancer-related (ICD C.61) health care services covered by NHIFA were captured including 
outpatient visits, laboratory tests, diagnostic imaging, hospitalisation, radiation therapy and 
prescription drug costs. Costs from the date of diagnosis to date of death or to 31 October, 2013 
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were considered. For each year after diagnosis, total incidence costs included only those 
patients who survived the year before. Average exchange rate of EUR/HUF = 296.92 was 
applied, and nominal costs were reported. 
 
Survival analysis 
Kaplan–Meier survival analysis for all-cause mortality were conducted in order to compare 
different subgroups of patients with PC. Differences between survival curves were tested by 
log-rank test. The Cox proportional hazards model was used for multivariate analysis to assess 
the relationship between PC and variables. Variables that proved significant in the univariate 
analysis were included in a forward stepwise multivariate Cox proportional hazards model in 
order to identify independent predictors in the overall PC population. P values of <0.05 were 
considered to indicate statistical significance. All analyses were conducted using R version 
3.1.3. 
 
Results 
 
Epidemiology 
During the study period, a total of 50,380 patients with prostate cancer were identified from the 
database (Figure 1). Patients diagnosed before January 1st, 2002 and after December 31st, 2005 
were excluded (n=32,738) and the remaining cohort of 17,642 patients diagnosed between 2002 
and 2005 were analysed. Their mean (SD) age at diagnosis was 69.5 (9.0) years and half of the 
patients were older than 70 years. Altogether 2,185 (12%) patients went through RP. These 
patients were typically diagnosed at a younger age than nRP patients (59.4 vs. 71.0; p<0.001). 
The overall mortality rate was 5.6-fold (95% CI: 5.0-6.4) higher among nRP patients. 
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Bone metastasis occurred in 1,380 (7.8%) patients. The average age at diagnosis was marginally 
different between the patient groups with and without bone metastasis (68.7 vs. 69.6; p<0.001). 
The overall mortality was 1.3-fold (95% CI: 1.20-1.31) higher in patients who developed bone 
metastasis.  
 
Survival 
Mean survival time of RP patients was significantly longer than that of nRP patients (11.2 vs. 
7.4 years; p<0.001) (Figure 2). Controlling for the age at diagnosis and bone metastasis, radical 
prostatectomy had the most significant effect on mortality hazard (Table 2). RP patients had a 
6.6 times lower mortality hazard compared to nRP patients. Patients younger than the age of 70 
years indicated a similar mortality hazard, but the difference between the survival times was 
still significant (11.3 vs 8.8 years; p<0.001) and the mortality hazard was 5.8 times lower.  
 
Costs 
Table 3 summarizes the annual and cumulative long-term costs of the patients. The mean total 
cumulative costs for the whole study population were €8,100 (SD 7,192). The main cost drivers 
were drugs (77%) and costs of hospitalization (including surgery) (19%). RP patients had 
significantly lower long-term total costs compared with nRP patients (€4,448 vs. €8,616). 
 
 
Discussion 
Principal findings 
In this study, we estimated the long-term total costs of prostate cancer in the RP and nRP 
patients and the overall survival in these two groups of patients using an insurance claims 
database in Hungary covering approximately 10 million people. To our best knowledge, this is 
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the second study in the literature estimating long-term incidence costs of prostate cancer in 
Europe. 
 
The overall long-term costs were almost twice as high in nRP group compared with the RP 
group; a surprising finding given that survival was shorter in nRP group. Our results showed 
that prescription drugs accounted for the majority of costs in nRP group (79%). Mean drug 
costs were almost 3.5-fold higher in nRP group (€6,829) than in RP group (€2,013). In the RP 
group, inpatient hospital stay (45%) and drug costs (45%) were responsible for the majority of 
costs. Mean inpatient hospital stay costs were 1.5 times higher in RP (€2,022) than in nRP 
groups (€1,433). These results demonstrate that the cost differences could be mainly explained 
by higher drug costs in the RP group. 
 
Comparison with other studies reporting long-term incidence costs 
In the US, analysing the SEER-Medicare data Stokes et al. estimated that the aggregated life-
time incidence costs of prostate cancer patients diagnosed in 2008 was as high as $34,432 [6]. 
Only patients older than 65 years were included in their analysis. Using survival estimation and 
claims data, they developed a phase-base model to predict life-time costs. In a population based 
study from the UK, Laudicella et al. reported that the total costs of prostate cancer patients aged 
under and over 65 years for a 9 years period mounted to £18,056 and £26,806, respectively [8]. 
In this study, cost data of the first 3 years were based on observation of a population-based 
cohort and costs of year 4 to 9 were estimated according to the hospital’s activity-based cost 
projection from a different cohort. However none of these studies reported costs by intervention 
types. 
 
Comparison with other Hungarian cost-of-illness studies in prostate diseases 
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Although two prior studies estimated the costs of prostate cancer treatment in Hungary, long-
term costs of prostate cancer have not been scrutinized so far [9,4]. In addition, these two studies 
failed to capture cost consequences of radical prostatectomy. Both studies have reported 
average annual costs of prostate cancer based on the NHIFA’s administrative database. In 2005, 
2008 and 2011 the average annual costs of prostate cancer were €3,336, €4,194 and €3,014 per 
case, respectively (due to the different exchange rates, the original reported results were 
converted) [4]. According to an official report by the NHIFA, prostate cancer-related average 
annual direct costs represented €11,114 in 2007, and €12,798 in 2010 [9]. Comparing with costs 
of other prostate diseases, total annual per patient cost of pharmacologically treated benign 
prostatic hyperplasia patients was merely €877 (SD €1,829) in Hungary [14]. However, a direct 
comparison between incidence long-term costs of a cohort and average annual costs of 
prevalent cases is pointless because of the methodological differences.  
 
Survival 
Our results showed that RP patients lived on average four years longer than nRP patients 
(p<0.001). Although RP patients were younger at the time of diagnosis and the majority of 
radical prostatectomy occurred under the age of 70 years, the differences in life-expectancy 
were independent of the age. In the subgroup of patients younger than 70 years, life-expectancy 
of RP patients was also significantly longer (2.5 years). In recently published studies, radical 
prostatectomy was associated with reduced risk of mortality compared both to watchful waiting 
(RR=0.56) and to androgen deprivation therapy (RR=0.33)[15-17]. Radical prostatectomy is a 
common treatment for patients with lower stage of prostate cancer and a good life-expectancy. 
Thus, our data might be a result of selecting patients with lower stage disease. However, the 
NHIFA database contains no data on disease severity, so the staging could not be included in 
the analysis as an explanatory variable. 
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In our study, at the end of the 12-year study period, the probability of being alive (Kaplan-
Meier survival estimate) was 0.83 and 0.35 for the RP and nRP patient groups. These data 
indicate that the RP patients had a higher probability of being alive at the end of the 12-year 
observation period than the age-matched general male population (0.83 vs. 0.68) [18]. In 
contrast, the nRP patients had a slightly lower probability of being alive compared with the age-
matched general male population (0.35 vs. 0.38) [18]. RP patients might be diagnosed at an 
early stage of the disease and have a better life-expectancy. In addition, there are evidences that 
patients diagnosed at early-stage PC might have higher socioeconomic status and better access 
to health care services compared to patients diagnosed at distant-stage [19]. We assume this 
explain  the longer life expectancy of this patient population compared with the general male 
population. 
 
Limitation 
This study has several limitations. First, this was a retrospective administrative claims database 
analysis; thus, the amount of clinical information available (e.g., tumor stage, grading, disease 
severity, therapeutic indication) is limited. This would be needed to stratify the sample by risk 
groups and conduct a more detailed analysis [20,21]. Furthermore, patients treated 
conservatively by choice or by disease status might be different regarding both survival and 
costs, but these groups could not be differentiated based on retrospective claims data. Claim 
database did not contain information on cause of death, only occurrence of death was recorded. 
Cause specific survival estimation would be more accurate when comparing subgroups among 
prostate cancer patients. Secondly, in administrative healthcare database studies that using ICD 
codes misclassification of claims might occur. However, besides ICD codes, exclusively codes 
of prostate cancer-related interventions were used for the patient selection, which is a strength 
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of our analysis. Thirdly, costs of primary care were excluded from this study, because prostate 
cancer-related primary care costs were not available in the NHIFA database due to 
reimbursement techniques, such as capitation. Fourthly, the simple mean was used for 
estimating the costs for the cohort of patients. Estimates based on the mean may bias the costs 
downward because costs occurred after the observed follow-up are equated to zero. 
 
Conclusions 
 
Using insurance claims database between 2002 and 2013 our study has the longest time-window 
in Europe analysing incidence total long-term costs and survival of RP and nRP prostate cancer 
patients. We found that RP patients lived longer. Beside longer survival, cumulative long-term 
costs were lower in RP group compared to nRP group. Most of the difference was attributable 
to higher drug costs in nRP group. Compared to conservative therapy, RP is a cost-effective 
treatment strategy in prostate cancer. 
Although it has been already proved that radical prostatectomy provides better overall survival 
in patients with prostate cancer, there is very few data on financial benefits. Thus, our results 
showed that find the disease in early, curative stadium has not only medical but also financial 
advantage.  
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No radical prostatectomy, no 
endocrine therapy, no 
radiotherapy N=12,850 
Year of diagnosis: 
-before 2002: 14,466 
-after 2005: 18,474 
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Figure 1 Selection process 
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Table 1 Main characteristics of patients 
Variables Patient with 
prostate cancer 
Patients having 
radical 
prostatectomy 
(RP) 
Patients without 
prostatectomy 
(nRP) 
Number of patients 17,642 2,185 15,457 
Age at diagnosis (year), mean (SD) 69.5 (9.0) 59.4 (5.9) 71.0 (8.4) 
Died, % (n) 52.3% (9,221) 10.3% (226) 57.9% (8,955) 
Bone metastasis, % (n) 7.8% (1,380) 5.1% (111) 8.2% (1,269) 
Survival (year), mean (SD) 7.8 (4.3) 11.2 (1.9) 7.4 (4.3) 
Mean time between diagnosis and radical 
prostatectomy or endocrine treatment 
(year), mean (SD) 2.4 (3.1) 4.3 (3.3) 2.2 (3.0) 
Received endocrine treatment 92.8% (16,366) 44.3% (967) 99.2% (15,339) 
Number of patients with survival time    
< 1 year 6.4% (1,131) 0.0% (1) 7.3% (1,130) 
1-5 years 24.8% (4,372) 3.2% (70) 28.3% (4,372) 
5< years  68.8% (12,139)  96.8% (2,114) 64.9% (10,025) 
 
Table 2 Uni- and multivariate survival analysis, Cox proportional-hazards model 
   Univariate Multivariate 
Variable N Survival 
(years) 
Hazard ratio 
(95% CI) 
p  Hazard ratio 
(95% CI) 
p 
Age at diagnosis       
     <70 years 8,428 9.3 2.93 (2.81-3.06) <0.001 2.39 (2.28-2.49) <0.001 
     ≥70 years 9,214 6.3     
Having bone metastasis       
     no 16,262 7.9 1.32 (1.23-1.42) <0.001 1.44 (1.34-1.54) <0.001 
     yes 1,380 7.2     
Radical prostatectomy       
     no 15,457 7.4 0.12 (0.11-0.14) <0.001 0.15 (0.13-0.17) <0.001 
     yes 2,185 11.2     
Long-term costs       
     below the median 8,821 7.0 0.70 (0.67-0.72) <0.001 0.50 (0.48-0.52) <0.001 
     over the median 8,821 8.7     
 
17 
 
Table 3 Yearly and long-term incidence cost of prostate cancer (in €) 
Year 
from 
diagns
osis 
N Outpatient Inpatient Drug CT Total 
no RP RP no RP RP no RP RP no RP RP no RP RP no RP RP 
Year 0* 15,457 2,185 22 (48) 12 (40) 180 (423) 166 (407) 484 (668) 73 (286) 8 (36) 10 (37) 693 (928) 261 (625) 
Year 1 14,939 2,185 31 (57) 16 (47) 226 (713) 212 (554) 986 (1 074) 169 (614) 11 (46) 12 (43) 1,254 (1,422) 408 (961) 
Year 2 13,639 2,178 29 (57) 14 (36) 167 (764) 123 (424) 887 (1 067) 202 (721) 9 (43) 10 (42) 1,092 (1,413) 349 (924) 
Year 3 12,366 2,164 29 (59) 17 (40) 147 (862) 138 (562) 814 (1 045) 210 (682) 8 (42) 12 (52) 998 (1,453) 377 (969) 
Year 4 11,337 2,139 27 (56) 19 (46) 136 (844) 152 (597) 754 (1 007) 224 (710) 9 (45) 16 (56) 926 (1,412) 412 (1,004) 
Year 5 10,440 2,126 25 (54) 23 (50) 119 (763) 183 (662) 715 (979) 231 (661) 8 (42) 20 (65) 867 (1,341) 456 (1,038) 
Year 6 9,626 2,105 24 (55) 27 (62) 111 (729) 223 (796) 675 (934) 233 (599) 9 (45) 21 (69) 820 (1,284) 505 (1,118) 
Year 7 8,816 2,077 22 (58) 31 (72) 112 (728) 239 (773) 573 (853) 232 (594) 9 (47) 22 (64) 717 (1,229) 523 (1,098) 
Year 8 8,038 2,049 21 (54) 29 (55) 101 (691) 248 (837) 457 (746) 211 (543) 10 (47) 25 (70) 588 (1,123) 514 (1,084) 
Year 9 5,633 1,483 15 (53) 22 (52) 68 (551) 178 (688) 284 (608) 136 (468) 7 (42) 17 (57) 374 (918) 353 (936) 
Year 10 3,532 938 9 (42) 14 (40) 46 (480) 120 (711) 139 (391) 66 (269) 5 (36) 11 (47) 200 (706) 210 (848) 
Year 11 1,686 430 4 (33) 7 (46) 20 (297) 41 (313) 61 (286) 26 (157) 2 (19) 5 (31) 86 (469) 79 (428) 
Cumula
tive 15,457 2,185 259 (285) 233 (238) 1,433 (3,101) 2,022 (2,455) 6,829 (6,137) 2,013 (4,337) 96 (231) 180 (269) 8,616 (7,237) 
4,448 
(5,701) 
Cost data were collected in calendar years unit. * Length of year 0 might vary between 0-365 days.  
 
nRP= patients without prostatectomy; RP= patients having radical prostatectomy 
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Figure 2 Kaplan-Meier survival analysis for all-cause mortality 
 
 
 
